A Phase 1/2 Dose Escalation/Expansion Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Latest Information Update: 07 Oct 2024
At a glance
- Drugs NGM 707 (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Biliary cancer; Carcinoma; Cervical cancer; Colorectal cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors NGM Biopharmaceuticals
- 04 Jun 2024 Interim results (As of November 6, 2023; n=82) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 03 Jun 2024 Status changed from recruiting to active, no longer recruiting.
- 29 May 2024 According to a Florida Cancer Specialists & Research Institute media release, interim data from this study will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.